SG11201908166UA - Usl-311 for use in the treatment of cancer - Google Patents

Usl-311 for use in the treatment of cancer

Info

Publication number
SG11201908166UA
SG11201908166UA SG11201908166UA SG11201908166UA SG 11201908166U A SG11201908166U A SG 11201908166UA SG 11201908166U A SG11201908166U A SG 11201908166UA SG 11201908166U A SG11201908166U A SG 11201908166UA
Authority
SG
Singapore
Prior art keywords
international
pct
treatment
proximagen
minerva
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Proximagen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Llc filed Critical Proximagen Llc
Publication of SG11201908166UA publication Critical patent/SG11201908166UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201908166U 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer SG11201908166UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201908166UA true SG11201908166UA (en) 2019-10-30

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908166U SG11201908166UA (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Country Status (14)

Country Link
US (1) US20200281937A1 (cg-RX-API-DMAC7.html)
EP (1) EP3592356A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020514345A (cg-RX-API-DMAC7.html)
KR (1) KR20190128660A (cg-RX-API-DMAC7.html)
CN (1) CN110520130A (cg-RX-API-DMAC7.html)
AU (1) AU2018231664A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019018482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055470A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992130A1 (cg-RX-API-DMAC7.html)
GB (1) GB201703907D0 (cg-RX-API-DMAC7.html)
IL (1) IL269121A (cg-RX-API-DMAC7.html)
MX (1) MX2019010679A (cg-RX-API-DMAC7.html)
SG (1) SG11201908166UA (cg-RX-API-DMAC7.html)
WO (1) WO2018162924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JP6927882B2 (ja) 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
JP6927882B2 (ja) * 2015-04-02 2021-09-01 プロキシマジェン,リミティド ライアビリティ カンパニー 癌の新治療法
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Also Published As

Publication number Publication date
MX2019010679A (es) 2020-02-05
JP2020514345A (ja) 2020-05-21
IL269121A (en) 2019-11-28
AU2018231664A1 (en) 2019-09-26
WO2018162924A1 (en) 2018-09-13
EP3592356A1 (en) 2020-01-15
CN110520130A (zh) 2019-11-29
GB201703907D0 (en) 2017-04-26
BR112019018482A2 (pt) 2020-04-14
CA3055470A1 (en) 2018-09-13
US20200281937A1 (en) 2020-09-10
KR20190128660A (ko) 2019-11-18
EA201992130A1 (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201811148SA (en) Cell penetrating peptide (cpp)-mediated ev loading
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201804934PA (en) Novel Compounds
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201909168VA (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201805072PA (en) Nicotine powder delivery system
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201908228TA (en) Chemical compounds
SG11201909224QA (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201809031XA (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
SG11201907199QA (en) Cancer treatment
SG11201900043TA (en) Antibody formulations